Human studiesGLP-1 agonist and GIP-receptor blocker (antibody–peptide conjugate)
Maridebart cafraglutide
MariTide, AMG 133
Common dose
140–420 mg every 4 weeks (trials)
Cycle
Continuous
Form
In trials only
An investigational injection given once a month or less often: an antibody that blocks the GIP receptor, carrying two GLP-1-like peptides. The GLP-1 part curbs appetite; blocking GIP, a gut hormone, added to weight loss in animal studies.
Evidence. Investigational (Amgen). In a 52-week phase 2 trial (592 adults), weight fell 12.3–16.2% vs 2.5% on placebo in people without diabetes and 8.4–12.3% vs 1.7% in people with type 2 diabetes, counting everyone randomized; up to 19.9% and 17.0% if all had stayed on treatment, per Amgen. Phase 3 (MARITIME) began in March 2025; its two main 72-week weight trials are due to finish in early 2027, and it isn’t approved anywhere.
What it’s used for
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
Weight loss in obesity
TrialPromising: in a 52-week phase 2 trial (465 adults without diabetes), weight fell 12.3–16.2% vs 2.5% on placebo, counting everyone randomized. Phase 3 weight trials report from 2027.
Weight loss with type 2 diabetes
TrialPromising: in 127 adults with type 2 diabetes, weight fell 8.4–12.3% vs 1.7% on placebo at 52 weeks, and HbA1c, a 3-month blood sugar average, 1.2–1.6 points vs a 0.1 rise.
Type 2 diabetes (blood sugar control)
TrialPromising but unpublished: in a 24-week phase 2 trial of 409 adults, Amgen reported clinically meaningful falls in HbA1c and weight (February 2026) without giving numbers. Phase 3 diabetes trials start in 2026.
Keeping weight off with fewer doses
TrialPromising but unpublished: Amgen says most people who lost 15% or more in year one kept it off for another year on lower monthly or every-12-week doses (February 2026).
Heart disease and heart failure
TrialUnproven: MARITIME-CV (about 12,800 adults) and MARITIME-HF (about 5,000) are testing whether it prevents heart attacks, strokes or heart failure events; completion is expected in 2030.
Obstructive sleep apnea
TrialUnproven: two phase 3 trials (MARITIME-OSA-1 and -2, about 250 adults each) are measuring breathing pauses during sleep at 52 weeks; main results are expected from late 2027.
Not approved anywhere. Phase 3 (MARITIME) began in March 2025: MARITIME-1 (3,853 adults without diabetes) and MARITIME-2 (1,105 with type 2 diabetes) run 72 weeks and are due to finish in early 2027, and heart, heart failure and sleep apnea trials are under way. Amgen hadn’t announced a filing as of October 2026.
US compounding
Never nominated for FDA’s 503A or 503B bulk lists (503A list updated May 14, 2026), and it isn’t part of any approved drug, so it doesn’t qualify for US compounding.
European Union
No marketing authorization.
United Kingdom
No marketing authorization (MHRA).
Canada
No marketing authorization; no maridebart cafraglutide product is listed in Health Canada’s Drug Product Database.
Australia
No marketing authorization, and maridebart cafraglutide isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026)
Likely banned in sportNot named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
How it works
Maridebart cafraglutide is a lab-made antibody that blocks the GIP receptor, the target of a gut hormone released after meals, with two GLP-1-like peptides attached that switch on the GLP-1 receptor to curb appetite. In mice and monkeys, blocking GIP on top of GLP-1 action increased weight loss. The antibody keeps it in the blood for weeks: in people, the intact drug’s half-life was about 14–16 days.
TrialMainly from studies in people.
Not known
Why blocking GIP aids weight loss when tirzepatide, which activates the GIP receptor, does too is unexplained. GIP receptors also sit in bone and fat; long-term effects on bone and the heart await phase 3.
Protocol
Trial
Jastreboff, NEJM 2025
Phase 2: 140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, for 52 weeks. Without diabetes, weight fell 12.3–16.2% vs 2.5% on placebo, counting everyone randomized.
Trial
Jastreboff, NEJM 2025
Phase 2 step-up arms: a lower first dose, reaching 420 mg every 4 weeks after 4 or 12 weeks. Stomach side effects were less frequent than with a full first dose.
Trial
Amgen, June 2025
Phase 3 (MARITIME): 21 mg, then 35 mg, then 70 mg over 8 weeks, then one of three undisclosed target doses, for 72 weeks.
Frequency
Every 4 weeks (every 8 weeks in one phase 2 arm)
Route
Subcutaneous injection (trials)
Cycle
Continuous in trials (52–72 weeks); maintenance with fewer doses is being tested.
Week 15913172125
Continuous, shown over 26 weeks
Common protocols
The ways Maridebart cafraglutide is most often run, each tagged with where it comes from.
Phase 2, monthly
Trial
Dose
140, 280 or 420 mg
How often
Every 4 weeks (420 mg also every 8 weeks)
How long
52 weeks
Full dose from the first injection. Without diabetes, weight fell 12.3–16.2% vs 2.5% on placebo across the arms, counting everyone randomized; 16.3–19.9% vs 2.6% if all had stayed on treatment (Amgen).
Phase 2, step-up
Trial
Dose
Lower start, rising to 420 mg
How often
Every 4 weeks
How long
4- or 12-week step-up, 52 weeks in all
Fewer stomach side effects than a full first dose. About 11% stopped for any side effect, and up to 7.8% for stomach side effects (Amgen).
Phase 3 (MARITIME)
Trial
Dose
21 mg, then 35 mg, then 70 mg, then one of three target doses
How often
Step-up over 8 weeks; dosing interval not published
How long
72 weeks
Target doses haven’t been disclosed. The two main weight trials (about 5,000 adults) are due to finish in early 2027.
Maintenance (phase 2, part 2)
Trial
Dose
70, 140 or 420 mg, or 420 mg every 12 weeks
How often
Every 4 or 12 weeks
How long
52 more weeks
For people who lost 15% or more in year one. Amgen says most kept the weight off on lower monthly or quarterly doses; no figures published.
Taking it
Where it goes
Injected under the skin in trials. Amgen plans a single-dose autoinjector, and phase 1 studies compared two injectable presentations.
If you miss a dose
No published guidance; no trial has reported a missed-dose rule.
Nausea and vomiting cluster after the first dose. In phase 2, nausea lasted a median of about 6 days and vomiting 1–2 days (Amgen).
Trial
Week 12
Phase 1: weight fell 14.5% by day 85 at 420 mg every 4 weeks vs a 1.5% gain on placebo (groups of 6–8), and was still 11.2% down 150 days after the last dose.
Trial
Week 52
Phase 2: weight 12.3–16.2% lower vs 2.5% on placebo, counting everyone randomized; 16.3–19.9% vs 2.6% if all had stayed on treatment. Weight hadn’t plateaued.
Trial
Year 2
In the phase 2 extension, Amgen says most people who had lost 15% or more kept it off on lower monthly or quarterly doses (no figures published).
Trial
Side effects and what to do
Nausea and vomiting, mainly after the first dose (phase 1, three monthly doses: nausea 67–100%, vomiting 67–83% vs 17% and 0% on placebo, 6–8 people per group)
A lower first dose and step-ups made them less frequent in phase 2; phase 3 starts at 21 mg.
Stopping because of side effects (phase 2 step-up arms: about 11% for any side effect, up to 7.8% for stomach side effects)
Higher in arms that started at the full dose, per Amgen.
Faster heart rate (phase 1: up 13.6 beats a minute at 21 mg and 4.2 at 840 mg, 5 days after a single dose, within the normal range)
No palpitations or racing heart were reported as side effects. Report a racing pulse at rest.
Constipation, diarrhea and indigestion
Reported in phase 1 and listed among common stomach side effects in phase 2; mostly mild.
Stop and get medical help
Severe belly pain that won’t go away, signs of allergy, a racing heart at rest or fainting, or dehydration (dizziness, very little urine). Get medical help.
Can it cause …?
The side effects people ask about most, answered one by one. Each answer says where it comes from.
Nausea or vomiting
TrialVery common after the first dose: in phase 1, nausea hit 67–100% and vomiting 67–83% over 3 monthly doses vs 17% and 0% on placebo; step-ups reduced it.
Diarrhea or constipation
TrialConstipation (up to 33%) and diarrhea (up to 25%) occurred in phase 1 groups of 6–8 people, and both are listed among common stomach side effects in phase 2.
Acne, rash or skin changes
Not reportedRash or injection-site reactions aren’t among the side effects highlighted in published summaries of the phase 1 and phase 2 trials.
Anxiety, low mood or irritability
Not reportedMood changes haven’t been reported in published summaries. Trials excluded recent major depression and any past suicide attempt, so data in those groups are lacking.
Low or high blood sugar
TrialIt lowers blood sugar: HbA1c fell 1.2–1.6 points vs a 0.1 rise on placebo in type 2 diabetes. No low blood sugar events were reported in phase 1 (no diabetes).
Fast heartbeat or blood pressure changes
TrialIn phase 1, heart rate rose after single doses (by 13.6 beats a minute at 21 mg, 4.2 at 840 mg), within the normal range; no palpitations were reported.
More hunger
Not reportedMore hunger hasn’t been reported. In phase 1, weight was still 11.2% down 150 days after the last 420 mg dose (a small group).
Liver strain
TrialOne raised liver enzyme result was reported in phase 1 (1 of 6 after a single 280 mg dose). A liver-impairment drug-level study finished in 2026, unpublished.
Kidney problems
PrecautionNo kidney problems have been reported; a kidney-impairment study finished in 2025, unpublished. With related GLP-1 drugs, dehydration from vomiting has caused kidney injury.
Cancer risk
PrecautionNo cancer signal has been reported. Approved GLP-1 drugs carry a thyroid C-cell tumor warning from rodent studies, and these trials exclude people with medullary thyroid cancer or MEN 2.
TirednessHeadacheDizzinessTrouble sleepingHair lossWater retention or swellingJoint or muscle pain
Not reportedNot among the side effects highlighted in published summaries of the phase 1 and phase 2 trials (up to 52 weeks).
Trial: reported in human studies. Precaution: a concern that follows from how it works or from a related drug, not measured. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
Who should avoid it
No product label covers maridebart cafraglutide (MariTide), so these come from human studies and from precautions based on how it works. Most important first.
History of medullary thyroid cancer or MEN 2
TrialA personal or family history excluded people from the phase 2 and 3 trials. Approved GLP-1 drugs are ruled out for this group because of thyroid C-cell tumors in rodents.
History of pancreatitis
TrialExcluded from phase 2 (any history) and phase 3 (chronic, or acute in the past 6 months). Pancreatitis, sometimes fatal, is a listed risk of approved GLP-1 drugs.
Recent depression or a past suicide attempt
TrialThe trials excluded major depression in the past 2 years and anyone who had ever attempted suicide, so there are no data in these groups.
Diabetic eye disease needing treatment
TrialExcluded from MARITIME-2. Semaglutide’s label warns that diabetic retinopathy, eye damage from diabetes, can worsen when blood sugar improves quickly.
Pregnancy or breastfeeding
PrecautionNo human safety data exist. It stays in the body for weeks, and antibodies of its type cross the placenta.
Anyone relying on product quality
PrecautionIt isn’t approved anywhere; anything sold as MariTide has no regulated standard for identity, purity or sterility, and lab-reagent listings aren’t made for people.
Interactions
No interaction results have been published, and no product label lists any. A study with an anti-nausea medicine finished in 2025 and a birth-control-pill study is under way; neither has published results. A 2025 stomach-emptying study is also unpublished.
Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
Special situations
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
Pregnancy
PrecautionNo human data. Antibodies of its type (IgG1) normally cross the placenta, mainly late in pregnancy, and a dose lasts weeks. Related approved drugs harmed fetal development in animals.
Breastfeeding
PrecautionNo human data; it isn’t known whether it passes into breast milk.
Kidney problems
PrecautionA drug-level study in kidney impairment (44 people) finished in November 2025 but isn’t published. Vomiting can dehydrate and injure the kidneys, as with related drugs.
Liver problems
PrecautionA drug-level study in liver impairment (36 people) finished in February 2026, unpublished. A phase 2 trial in adults with excess liver fat is under way.
Older adults
PrecautionThe phase 2 and 3 trials set no upper age limit; no results by age have been published.
Children and teens
PrecautionNot studied in anyone under 18, and no trial in children or teens is registered.
Surgery and anesthesia
PrecautionNo data. Related GLP-1 drugs slow stomach emptying, and their labels warn that stomach contents can enter the lungs under anesthesia; a dose lasts weeks. Tell the surgical team about any injected compound.
Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Tracking and pairing
Worth tracking
Resting heart rate
Blood sugar with insulin or a sulfonylurea
Kidney function if vomiting is heavy
Eye checks with diabetic retinopathy
Often paired with
Usually run on its own.
Human studies
2 key published human studies, with how many people took part. Animal studies aren’t listed here.
2025592 people
Without diabetes (465), weight fell 12.3–16.2% vs 2.5% on placebo; with type 2 diabetes (127), 8.4–12.3% vs 1.7%, and HbA1c 1.2–1.6 points vs a 0.1 rise, counting everyone randomized.
140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks; two arms stepped up
Length
52 weeks
Jastreboff et al., N Engl J Med 2025, PMID 40549887
202475 people
At 420 mg every 4 weeks, weight fell 14.5% by day 85 vs a 1.5% gain on placebo; 4 of 8 in that group left after the first dose because of mild stomach side effects.
Design
Phase 1 randomized double-blind placebo-controlled single and multiple ascending dose study
Dose
21–840 mg once, or 140–420 mg every 4 weeks for 3 doses
Length
Single dose or 12 weeks, with follow-up to day 207
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
Phase 3NCT06858839
MARITIME-1: three doses vs placebo for 72 weeks in 3,853 adults with obesity or overweight without diabetes: weight change
Active, not recruiting; main results expected early 2027, completion April 2027
Phase 3NCT06858878
MARITIME-2: three doses vs placebo for 72 weeks in 1,105 adults with obesity or overweight and type 2 diabetes: weight change
Active, not recruiting; main results expected early 2027, completion April 2027
Phase 3NCT07037433
MARITIME-CV: maridebart cafraglutide vs placebo in about 12,800 adults aged 45 or older with heart or blood vessel disease and excess weight: heart attacks, strokes and heart deaths
Recruiting; completion expected September 2030
Phase 3NCT07037459
MARITIME-HF: maridebart cafraglutide vs placebo in about 5,056 adults with obesity and heart failure with preserved or mildly reduced pumping: heart deaths and heart failure events
Recruiting; completion expected September 2030
Phase 3NCT07575399
MARITIME-SWITCH: two dosing schedules in about 300 adults switching from a weekly GLP-1 drug: weight change at 68 weeks (open label)
Recruiting since May 2026; completion expected February 2028
Published human data cover 75 people in phase 1 and 592 in a 52-week phase 2 trial. Results from the phase 2 extension, a 409-person diabetes trial and several drug-level studies exist only as brief company statements or not at all. Phase 3 weight trials (about 5,000 adults, 72 weeks) report from 2027, heart outcome trials run to 2030, and long-term bone, heart and pregnancy safety are unknown.
How it’s supplied
Injections of 140–420 mg every 4 or 8 weeks in phase 2; phase 3 starts at 21 mg and steps up. Not sold. Injected under the skin once a month or less often in trials; Amgen plans a single-dose autoinjector. It’s available only in clinical trials, so the calculator and dose log don’t apply.
Datasheet
Half-life
about 14–16 daysTrialIntact molecule after a single injection under the skin in adults with obesity; the antibody part lasts 21–24 days. Levels peak 4–7 days after a dose.
Type
Protein
Molecular weight
about 144,800 g/mol for the antibody chains alone (calculated; excludes the two peptides)
Formula
C6416H9898N1718O1994S48 (antibody chains only)
Sequence
Human IgG1 antibody against the GIP receptorTwo 450-residue heavy and two 214-residue light chains); each heavy chain is joined at an added Cys275 to the GLP-1 analog H(Aib)EGTFTSDYSSYLEEQAAKEFIAWLVKGGG plus a (GGGGS)3-Lys linker
Storage before use
No label or published storage data; trial supplies are handled by the sponsor.
After mixing or opening
Not applicable: no product is sold outside trials.
Half-life: Véniant et al., Nat Metab 2024, PMID 38316982
Molecule: FDA substance registry, UNII Z24U3U73HN (INN structure; calculated formula and weight); Véniant et al., Nat Metab 2024 (peptide sequence)
Storage:Community No approved label exists; no storage data have been published for this compound
No approved product; trials inject it under the skin, and Amgen plans a single-dose autoinjector. It is a large antibody made in living cells, not a short peptide; chemical-supplier listings are for lab use only, with no regulated standard for identity, purity or sterility.
Cautions
Investigational and not approved anywhere; long-term safety is still being studied in phase 3.
Nausea and vomiting were very common after a full first dose; step-ups cut them in phase 2, and phase 3 starts at 21 mg.
Each dose lasts weeks: the intact drug’s half-life is about 2 weeks, so side effects may not ease soon after a dose.
It is a large antibody made in living cells, not a simple peptide. Anything sold as MariTide has no regulated standard for identity, purity or sterility.
Questions
What is maridebart cafraglutide (MariTide)?
An investigational injection given once a month or less often: an antibody that blocks the GIP receptor, carrying two GLP-1-like peptides. The GLP-1 part curbs appetite; blocking GIP, a gut hormone, added to weight loss in animal studies.
How does maridebart cafraglutide (MariTide) work?
Maridebart cafraglutide is a lab-made antibody that blocks the GIP receptor, the target of a gut hormone released after meals, with two GLP-1-like peptides attached that switch on the GLP-1 receptor to curb appetite. In mice and monkeys, blocking GIP on top of GLP-1 action increased weight loss. The antibody keeps it in the blood for weeks: in people, the intact drug’s half-life was about 14–16 days. Why blocking GIP aids weight loss when tirzepatide, which activates the GIP receptor, does too is unexplained. GIP receptors also sit in bone and fat; long-term effects on bone and the heart await phase 3.
Is maridebart cafraglutide (MariTide) FDA-approved?
Not approved anywhere. Phase 3 (MARITIME) began in March 2025: MARITIME-1 (3,853 adults without diabetes) and MARITIME-2 (1,105 with type 2 diabetes) run 72 weeks and are due to finish in early 2027, and heart, heart failure and sleep apnea trials are under way. Amgen hadn’t announced a filing as of October 2026. Never nominated for FDA’s 503A or 503B bulk lists (503A list updated May 14, 2026), and it isn’t part of any approved drug, so it doesn’t qualify for US compounding.
What is the usual maridebart cafraglutide (MariTide) dose?
From human studies (Jastreboff, NEJM 2025): Phase 2: 140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, for 52 weeks. Without diabetes, weight fell 12.3–16.2% vs 2.5% on placebo, counting everyone randomized. Phase 2 step-up arms: a lower first dose, reaching 420 mg every 4 weeks after 4 or 12 weeks. Stomach side effects were less frequent than with a full first dose. These are the amounts sources reference, not recommendations.
How is maridebart cafraglutide (MariTide) given?
Injected under the skin once a month or less often in trials; Amgen plans a single-dose autoinjector. It isn’t sold: it’s available only in clinical trials.
Who should avoid maridebart cafraglutide (MariTide)?
No product label covers maridebart cafraglutide (MariTide), so these come from human studies and from precautions based on how it works. History of medullary thyroid cancer or MEN 2: A personal or family history excluded people from the phase 2 and 3 trials. Approved GLP-1 drugs are ruled out for this group because of thyroid C-cell tumors in rodents. History of pancreatitis: Excluded from phase 2 (any history) and phase 3 (chronic, or acute in the past 6 months). Pancreatitis, sometimes fatal, is a listed risk of approved GLP-1 drugs. Recent depression or a past suicide attempt: The trials excluded major depression in the past 2 years and anyone who had ever attempted suicide, so there are no data in these groups. The “Who should avoid it” section lists 3 more groups.
What is the half-life of maridebart cafraglutide (MariTide)?
About 14–16 days, measured in human studies. Intact molecule after a single injection under the skin in adults with obesity; the antibody part lasts 21–24 days. Levels peak 4–7 days after a dose.
How should maridebart cafraglutide (MariTide) be stored?
Before mixing: No label or published storage data; trial supplies are handled by the sponsor. After mixing: Not applicable: no product is sold outside trials. This is common practice; no product label covers it.
Is maridebart cafraglutide (MariTide) banned in sport?
Probably. Not named on WADA’s 2026 list, but its S0 rule bans drugs with no current human approval anywhere, at all times.
Has maridebart cafraglutide (MariTide) been studied in people?
Yes. The human studies section lists 2 published studies. The largest, from 2025, included 592 people. Without diabetes (465), weight fell 12.3–16.2% vs 2.5% on placebo; with type 2 diabetes (127), 8.4–12.3% vs 1.7%, and HbA1c 1.2–1.6 points vs a 0.1 rise, counting everyone randomized.
How long has maridebart cafraglutide (MariTide) been studied in people?
Trial About 2 years: in phase 2, people who lost 15% or more in year one could continue 52 more weeks (numbers unpublished). Phase 3 weight trials run 72 weeks.
Does maridebart cafraglutide (MariTide) come in other forms, like a pill or nasal spray?
Trial Only injections under the skin have been tested, once a month or less often; phase 1 studies compared two injectable presentations. No tablet or nasal form has been reported.
Can you drink alcohol while taking maridebart cafraglutide (MariTide)?
Precaution No data. Heavy drinking can itself cause pancreatitis, a listed risk of approved GLP-1 drugs.
Can maridebart cafraglutide (MariTide) be taken with semaglutide or tirzepatide?
Precaution It already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up. A phase 3 trial tests switching from weekly semaglutide or tirzepatide; none tests combining them.
What happens if you take too much maridebart cafraglutide (MariTide)?
Trial No label or overdose data. Single doses up to 840 mg in phase 1 mainly caused nausea and vomiting, and a dose lasts weeks. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
Sources
Jastreboff et al., once-monthly maridebart cafraglutide, phase 2 trial (N Engl J Med 2025) PMID 40549887
Véniant et al., preclinical and phase 1 results of AMG 133 (Nat Metab 2024) PMID 38316982
Amgen press releases: phase 2 results (November 2024; June 2025, with the phase 3 step-up), fourth-quarter 2025 results (February 2026), second-quarter 2026 results (August 2026)
MARITIME-1 phase 3 registry entry NCT06858839
For the protocol details
Amgen press releases: November 2024, June 2025 (phase 2 details, phase 3 step-up) and February 2026 (part 2 and diabetes trial)
For how it works, who should avoid it and the limits of the evidence
Wu et al., discovery of AMG 133 (J Med Chem 2026) PMID 41941715
Wegovy prescribing information, sections 5, 8 and 10, for class warnings (Novo Nordisk, DailyMed, rev. 06/2026)
FDA Global Substance Registration System record for maridebart cafraglutide (UNII Z24U3U73HN) and KEGG DRUG D13331 (checked October 8, 2026)
Health Canada Drug Product Database, WHO ATC index and Australian Poisons Standard, October 2026; ClinicalTrials.gov entries for the trials listed and completed drug-level studies (checked October 8, 2026)